FDA Delays Effective Date for Estrogen-Androgen Drug Product Notice

The FDA has extended the effective date of its notice regarding estrogen-androgen fixed-combination drug products by 90 days, moving it to September 24, 2026. This extension provides additional time for the agency to review concerns raised by stakeholders. The original notice questioned the effectiveness of these products for certain menopausal symptoms.